IFSO APC Pacific Chapter Session – Dr Ravi Rao at Melbourne 2024
About IFSO
The International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) is composed of 73 National Societies of Bariatric Surgeons and Integrated Health Professionals.IFSO’s mission is to unify the global scientific, surgical, and integrated health communities, for the purpose of dissemination of knowledge, collaboration and establishing universal standards of care for the treatment of individuals with adiposity-based chronic disease.
It focuses on Worldwide bariatric activities such as bariatric congresses, international meetings, coordination of scientific collaboration among various internal bariatric surgical organizations, collaboration with national governmental organizations and other international organizations such as the WHO.
The current President of IFSO is Professor Gerhard Prager and the Congress Co-Presidents are Associate Professor Ahmad Aly and Dr Harry Frydenberg AM.
For more information on IFSO please visit their website.
IFSO Melbourne 2024
IFSO Melbourne 2024 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) with 15.5 credits.
TOPIC: “The role of Duodenal Switch and SADI-S in patients with recurrent weight gain after RNY Gastric Bypaas and SADI-S as an emerging procedure in ASIA”
Dr Ravi Rao at IFSO 2024 – SADI-S procedure advancements
Studies show that SADI-S provides substantial long-term weight loss, with excess weight loss (EWL) rates of 87% at five years and 80% at ten years post-surgery. The procedure also demonstrates effective resolution of comorbidities such as type 2 diabetes and hypertension.
Research indicates that SADI-S has a lower incidence of nutritional deficiencies compared to traditional duodenal switch procedures, particularly when the common channel is extended to 300 cm, which reduces malabsorption risks.
The use of robotic assistance in SADI-S surgeries is increasing, with centers reporting successful outcomes and lower complication rates. This approach enhances precision and may improve recovery times.
Recent evaluations suggest that SADI-S outperforms sleeve gastrectomy (SG) in terms of weight loss and metabolic disease remission, with complete remission rates for type 2 diabetes reaching 100% within 12 months post-surgery.
The SADI-S procedure simplifies the traditional biliopancreatic diversion with duodenal switch (BPD-DS) by eliminating one anastomosis, which reduces operative time and the potential for complications.
The procedure is now being considered for a broader range of patients, including those who have previously undergone other bariatric surgeries. It has shown effectiveness as a revisional procedure after failed SG or other weight loss surgeries.
Long-term follow-up studies have indicated that SADI-S is a safe procedure with minimal postoperative complications, reinforcing its viability as a primary treatment for morbid obesity.
Patients report significant improvements in quality of life post-surgery, with manageable bowel movement patterns and overall satisfaction with weight loss outcomes.
The SADI-S technique is gaining traction globally, with numerous studies and clinical trials being conducted to further establish its efficacy and safety across diverse populations.
Continuous research is being conducted to optimize surgical techniques and postoperative care protocols, focusing on enhancing patient outcomes and minimizing nutritional deficiencies associated with the procedure.